Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions

This study has been completed.
Information provided by:
Sandoz Identifier:
First received: March 17, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
The purpose of this study is to demonstrate the bioequivalence of divalproex sodium 125 MG delayed release tablets.

Condition Intervention Phase
Drug: Divalproex Sodium
Drug: Depakote DR Tablets
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-Dose, Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence according to US FDA Guidelines [ Time Frame: 9 Days ] [ Designated as safety issue: No ]

Enrollment: 28
Study Start Date: October 2006
Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
Drug: Divalproex Sodium
Active Comparator: 2
Depakote 125 MG DR Tablets Abbott Laboratories USA
Drug: Depakote DR Tablets


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically significant findings on physical examination, medical history or laboratory tests on screening

Exclusion Criteria:

  • Positive test for HIV or Hepatitis B and C
  • History of sensitivity to valproic acid or related compounds
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00864006

Sponsors and Collaborators
Sandoz Inc.
Principal Investigator: Xueyu Chen, MD, Ph.D, FRCP(C) Pharma Medica Research, Inc.
  More Information

Responsible Party: Eric Mitleberg. Ph.D., VP Product Development, Sandoz, Inc. Identifier: NCT00864006     History of Changes
Other Study ID Numbers: 2006-1294 
Study First Received: March 17, 2009
Last Updated: March 17, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Valproic Acid
Antimanic Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Psychotropic Drugs
Tranquilizing Agents processed this record on May 26, 2016